STUDresearch · Non-peptide
Metformin
Also known as
Glucophage · Glucophage XR · metformin HCl · metformin hydrochloride · Fortamet · Glumetza · Riomet · metformin IR · metformin XR / ER / SR · metformin DR (delayed-release research formulations) · dimethylbiguanide (class/historical) · biguanide (class)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Some talk
Systemic
Oral
Metabolic & longevity adjacents
Systemic — oral biguanide with whole-body glucose and nutrient-sensing effects (liver glucose output, insulin sensitivity, gut/incretin pathways).
What people say
A prescription glucose-lowering drug that also draws longevity, PCOS and gym-community discussion. People compare appetite, glucose numbers, gut tolerance and training feel; healthy-aging interest is not proof of longer life.
Doses people talk about
This prescription drug's amounts depend on the indication, formulation and kidney function. These rows summarize existing discussion, not instructions.
How it may feel
Early reports often focus on nausea, diarrhea or bloating. Some improve, some stop, and others notice little beyond lab changes; training fatigue also appears in the notes.
Smaller longevity reports · off-label500 mg/day
Some existing community notes describe this amount for weeks; they do not establish it as safe for an individual.
Broader longevity discussion · off-label1000–2000 mg/day total
A daily total, not one dose. IR is often split; XR discussion commonly uses one daily administration. Formulations cannot be assumed equivalent for a person.
Half-life & effect duration
- Half-life in the body
- PlasmaAbout 6.2 hours
- Whole bloodAbout 17.6 hours
- Other plasma summariesAbout 4–9 hours
- Felt duration people report
- Fatigue accountsNext-morning fatigue; one extended-release user stopped after a month
- Digestive accountOccasional nausea or vomiting during months 1–3, later settling
Cycles people discuss
The existing discussion mainly describes ongoing daily use, not a short on/off cycle. Training-day breaks and evening-only experiments also appear, but are not proven superior routines.
Timing
Meals and IR-versus-XR tolerance dominate the timing discussion; XR is often described with the evening meal. Exercise-day skipping is a separate debate, not a result established by half-life.
Stacks
Rapamycin + metformin: Classic longevity polypharmacy pair; mouse combo lifespan talk exists; human users discuss glucose monitoring because both can hit nutrient-sensing pathways.
Access talk
Prescription generic IR / XR (Glucophage and copies) — cheap with a script, off-label for longevity. Not a research peptide.
Labs people mention
Glucose and HbA1c are the job labs. Longevity users still end up staring at the same numbers.
Watch for
GI (most common): Diarrhea, nausea, bloating, gas, abdominal pain, loss of appetite — worst at initiation and dose jumps; major reason for early quit.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
About 6.2 hours in plasma; the blood measurement is longer, about 17.6 hours.
Red-blood-cell partitioning helps explain the difference. XR/ER changes release and absorption; it is not simply a different elimination clock.
Kidney impairment prolongs exposure. Neither value predicts symptom duration, identifies a safe amount or establishes a healthy-aging benefit.
- Metformin label: elimination, indication and cautions (opens in a new tab)Section 12.3 Distribution, Elimination and Renal Impairment: approximately 6.2-hour plasma and 17.6-hour blood half-lives. Sections 1 and 5.3 plus Patient Information distinguish the US T2D indication and low-glucose risks.Label kinetics are not an individual symptom clock; renal impairment changes both. This is a US immediate-release label, not proof of off-label benefit or the cause of a forum user's symptoms.
Felt duration people report
One poster describes next-morning fatigue; another reports occasional nausea and vomiting during the first one to three months that later settled.
In the reviewed IR-versus-ER thread, one regular-tablet user also reports a skin change near one week and pre-existing low iron. An ER user stopped after a month because of fatigue.
Repeated-use anecdotes, not a single-dose duration or proof of low glucose/B12 as the cause. Formulations, PCOS and pre-existing symptoms differ.
- Metformin: regular-tablet and ER experiences (opens in a new tab)April 11, 2022 thread: sweetenermaz original/low-iron comments and unmeasured low-glucose explanation; Typical-Package-4765 ER nausea report; Possible_Sea7680 fatigue and stopping after a month. B12 and low-glucose suggestions in replies are not confirmed diagnoses.Individual, unverified accounts with different formulations and prior conditions; commenters' unmeasured hypoglycemia or vitamin explanations are not adopted as diagnoses.
Other context in this card
- TAME: proposed aging trial, not an efficacy result (opens in a new tab)Raising Funds to Launch and What is the status of the TAME Trial? sections: prepared design, donors and participants needed for launch; prospective goals rather than a results report.Program-organizer and fundraising page, not a trial-results paper or a comprehensive registry search. Its aspirations do not establish a healthy-aging benefit.
What people say
- Weight: Mild loss or weight-neutral; far weaker than GLP-1 / dual agonists for body-weight. forum
- Vs berberine: OTC plant alkaloid framed as “poor man’s metformin” / AMPK stand-in; glycemic head-to-heads exist in small studies, longevity winner unproven either way. forum
- Bodybuilding cut talk: Milder hepatic glucose output / nutrient-partitioning narrative during cuts or with exogenous insulin — not a primary anabolic. forum
- Stack halo problem: Often credited inside multi-drug longevity stacks (rapa + met + acarbose + NAD) where isolation is impossible. forum
- TAME status talk: 2026 writeups still disagree whether TAME is fundraising or enrolling; what they agree on is no published efficacy result for aging-as-the-indication. forum
- Glycemic control (T2D): Lowers fasting glucose and HbA1c; long-standing first-line oral therapy in guidelines. trial
- Diabetes delay (DPP): Diabetes Prevention Program — metformin ~850 mg twice daily reduced progression from prediabetes vs placebo (~31% relative risk reduction in original report; lifestyle still stronger). trial
- DPP long follow-up: DPPOS / multi-decade follow-ups still show residual risk reduction vs historical placebo arm (lifestyle remains the stronger signal in summaries). trial
- CV / mortality (T2D overweight): UKPDS-linked overweight cohorts frequently cited for lower diabetes-related endpoints and mortality signals on metformin. trial
- Observational longevity halo: Bannister-style and related analyses often retold as “diabetics on metformin sometimes match or beat non-diabetics” — selection bias and confounding remain active debates. trial
- Skepticism update: Later observational re-analyses and podcast/clinic discussion (e.g. Attia journal-club framing) push back that metformin is not a proven lifespan drug in healthy people. forum
- PCOS talk: Insulin resistance, androgen, and cycle-regularity narratives in clinic and community (off-label relative to pure T2D labeling). trial
- Cancer-risk observational interest: Mixed epidemiologic signals for lower incidence of some cancers in metformin users — not settled causality for healthy users. trial
- CR-mimetic / AMPK framing: Nutrient-sensing story used to justify non-diabetic use; human lifespan extension unproven. forum
- Animal aging models: Some rodent healthspan/lifespan signals at specific doses; higher-dose mouse work can fail or shorten life — dose-dependent and strain-dependent. animal
- ITP honesty: Metformin alone is not the standout NIA Interventions Testing Program winner the way rapamycin is; combo lore often pairs rapa with acarbose more than metformin. animal
- 2025–26 evidence mood: Ageing Research Reviews-style papers and Attia journal clubs pushed “emerging uncertainty” — an observational longevity halo in diabetics is not a license for metabolically healthy people. trial
- Diabetic-women longevity signal: 2025 WHI-style target-trial emulation (metformin vs sulfonylurea, survival to 90) is still a T2D comparison, not a healthy-person lifespan RCT. trial
Doses people talk about
- Longevity community band: Most-discussed ~1,000–2,000 mg/day continuous; TAME-design talk centers ~1,500 mg/day. forum
- Conservative longevity starts: ~500 mg/day (sometimes XR) for weeks before any climb; some clinic blogs describe 500 mg a few days/week first. forum
- Bodybuilding charts (forum/case-report culture): Cut-phase ~500 mg/day to ~500 mg BID; bulk/insulin-support talk sometimes 500–800 mg 1–2×/day — highly variable, not clinical standards. forum
- With food rule: Take with meals; empty-stomach IR is a classic GI fail. forum
- Public figure / influencer lore (not evidence): Commonly retold charts include ~1,000 mg/day (e.g. Sinclair-linked talk), ~1,500 mg/day (Barzilai-linked talk), ~500–850 mg/day (Kurzweil-linked talk), ~1,000–2,000 mg/day broader bro ranges — anecdote/branding, not RCTs. anecdote
- Titration step: Commonly +500 mg every 1–2 weeks (sometimes weekly) as GI allows. trial
- Classic IR split examples: 500 mg BID → 1000 mg BID; or 850 mg BID (DPP-style). trial
- MASTERS training trial dose: 1,700 mg/day (850 mg × 2 after a 2-week ramp) during progressive resistance training. trial
- Glucose plateau talk: Clinical write-ups often note diminishing extra glucose effect past ~1,600–1,700 mg/day for many patients. trial
- TAME design dose (not a published efficacy result): Planned non-diabetic older adults ~1,500 mg/day for multi-year aging-disease endpoints — funding/launch status has lagged; no published TAME efficacy win as of last research pass. trial
- MET-PREVENT-class frail elderly talk: 500 mg three times daily (~1,500 mg/day) studied short-term for physical performance — null primary walk-speed signals discussed as a caution against assuming functional wins. trial
- IR vs XR choice: XR preferred when GI is the limiter; efficacy for glucose often treated as roughly comparable at same total daily mg. trial
- Do not crush XR: Extended-release tablets generally swallowed whole (ghost tablet in stool is a known XR quirk, not failure). trial
- Renal dose reality: eGFR gates start, max dose, and continuation — low eGFR is not a “push through” situation. trial
- Uncertainty stack: Kidneys, IR/XR, food timing, other glucose-lowering drugs, illness, and contrast procedures all change risk and effective exposure. trial
- Framing: Discussed community, clinic, label, and trial ranges for research/education only — not advice or prescriptions. Metformin is a prescription drug with renal and lactic-acidosis cautions. forum
- IR start (common clinical pattern): ~500 mg once daily with a meal, then titrate. trial
- IR alternate start: ~500 mg twice daily or ~850 mg once daily depending on product/label and tolerance. trial
- T2D maintenance band: ~1,000–2,000 mg/day total — IR often split (e.g. 500–1000 mg with breakfast and dinner) or XR once daily. trial
- DPP / prediabetes trial dose: 850 mg once daily × ~1 month, then 850 mg twice daily (1,700 mg/day) with food, doses often ≥8 hours apart. trial
- XR start: Often 500 mg or 1,000 mg once daily with evening meal, then titrate. trial
- XR max (many products): ~2,000 mg/day once daily (some labels allow split XR if needed). trial
- IR labeled upper range: Product-dependent, often up to ~2,550 mg/day for some IR products — not a longevity target and not “more = better.” trial
How it may feel
- Days 1–14: GI window dominates — loose stools, diarrhea, nausea, bloating, gas, cramping; metallic taste common. forum
- Empty-stomach regret: First-week failures often traced to taking IR without food or jumping dose too fast. forum
- Weeks 2–4: GI often improves with food, slower titration, or switch IR → XR; some still quit here. forum
- Weeks 4–8: Labs (glucose/HbA1c if applicable) matter more than “feel”; no stimulant buzz expected. forum
- Months 1–3: Appetite may drift slightly down; weight change usually small and confounded by diet/training. anecdote
- Months 3–6: Assess whether GI is livable long-term; B12 conversation starts for continuous users. forum
- Month 6+: Sensation is often “nothing” — success criteria are labs, not mood or pumps. forum
- Training days: Some report flatter zone-2 / higher perceived effort or lactate (Attia-style anecdote); others notice nothing. anecdote
Around the dose
- Clock: With meals. Empty-stomach IR is the classic GI fail. XR often evening-with-dinner. forum
- Training: Some hold the dose on hard lift / zone-2 days after MASTERS / “blunts adaptations” papers — Attia-adjacent lore, not a longevity RCT winner. forum
- After: Walks and protein still get credited; the pill is not a GLP-1 appetite mute. forum
- Stack watch: If berberine or a GLP is also in the screenshot, 2025–26 threads watch overnight glucose instead of adding milligrams. forum
- Holds: Contrast, surgery, dehydration / illness — label culture, not a bro cycle. trial
Cycles people discuss
- Longevity default: Mostly continuous daily; minority experiments with training-day offs or evening-only dosing to spare exercise adaptations. forum
- Titration block: 1–4 weeks (sometimes longer) of slow ramp before judging tolerability or “no benefit.” forum
- Exercise-day skip lore: Some users hold metformin on hard lifting or key cardio days after MASTERS / mitochondrial-adaptation papers — not proven superior in longevity RCTs. forum
- Evening-only timing lore: Attia-style discussion of evening dose to reduce daytime exercise exposure while keeping nightly AMPK story — personal protocol talk, not a trial winner. anecdote
- Reassess triggers: Falling eGFR, B12 deficiency, persistent GI, new hypoxia/heart failure, or stacking more glucose drugs. forum
- Clinical T2D default: Continuous long-term daily use — not a short peptide-style 4–8 week cycle. trial
- Holds — severe illness / dehydration: Pause talk around acute kidney stress, sepsis risk, hypoxia, or heavy vomiting/diarrhea. trial
- Holds — iodinated contrast: FDA-label style: discontinue at/prior to iodinated contrast when eGFR 30–60, or with liver disease/alcoholism/heart failure history, or for intra-arterial contrast; recheck eGFR ~48 h before restart. ACR guidance is more permissive for many eGFR ≥30 IV-contrast cases without AKI — practices differ; research users should not invent a single universal rule. trial
- Holds — surgery: Institutional protocols vary; lactic-acidosis caution around major surgery, fasting, and renal risk is standard clinical culture. trial
- Not a blast/cruise drug: “Cycle length” talk is mostly wrong framing except for intentional holds and titration. forum
Timing
- Tissue / erythrocyte talk: Community notes discuss longer tissue/blood residence alongside 1–2× daily IR schedules. The label distinguishes blood from plasma measurements; neither establishes an individual dosing interval. forum
- IR split discussion: Breakfast/dinner or TID IR splitting appears in the existing GI-tolerance discussion instead of one large IR amount. Formulation, glucose response, tolerance and renal function matter; the schedule cannot be derived from half-life alone. forum
- Downstream pathways discussed: Hepatic gluconeogenesis ↓, AMPK-related signaling, Complex I interference, incretin (GLP-1/PYY) and microbiome shifts. forum
- Exercise timing debate: Some separate hard sessions from peak dose windows; evidence that timing fully solves hypertrophy/mito blunting is thin. forum
- Plasma half-life: Roughly ~4–9 hours (often cited ~5–6 hr class); essentially not metabolized — cleared renally. trial
- XR once-daily logic: Slower release, lower peaks, evening-with-meal culture for many XR products. trial
- Peak timing (IR vs XR): IR peaks earlier; XR peak delayed (often several hours later) — used to explain lower peak-related GI for some. trial
- Oral bioavailability: Incomplete (~50–60% class figures in PK reviews); saturable absorption — bigger single doses do not scale linearly. trial
- Gut-action story: Delayed-release research formulations can cut systemic exposure ~40–60% while preserving much of the glucose effect — supports “gut matters” mechanism talk. trial
- Renal dependence: Low eGFR prolongs exposure and raises lactic-acidosis risk — the hard safety gate. trial
- Drug interaction vigilance: Cationic renal-transport competitors and alcohol excess appear in caution lists; full interaction review is clinical, not forum folklore. trial
More on what it is
- Why people search it: Longevity baseline candidate (TAME-adjacent), huge diabetes evidence base, cheap generics, and constant stack talk with rapamycin / NAD / berberine. forum
- Mechanism (simple talk): Lowers hepatic glucose production, improves insulin sensitivity; AMPK and mitochondrial Complex I stories dominate forums; gut/GLP-1/microbiome pathways are increasingly discussed. forum
- Research lens: Match claims to IR vs XR, real dose, kidneys (eGFR), B12, exercise goals, and other glucose drugs — not brand lore or influencer dose charts. forum
- Longevity vs the label (2025–26): The US label is for Type 2 diabetes; prediabetes, PCOS and longevity are separate off-label discussions. AFAR's TAME page still describes fundraising to launch, not a healthy-aging efficacy result. Longevity clinics writing 1,000–1,500 mg off-label is a different conversation from Glucophage for A1c. trialforum
- What it is: Oral biguanide prescription drug (Glucophage and many generics); first-line Type 2 diabetes medicine for decades. trial
- Evidence honesty: Strong RCT support for glucose/HbA1c and diabetes delay (DPP); pure healthy-aging hard endpoints still pending (TAME not published as efficacy win). trial
- Not this: Not a peptide, not a GLP-1 agonist, not a stimulant fat-burner, not a proven “anti-aging pill” for non-diabetics. trial
Stacks
- Rapamycin + metformin: Classic longevity polypharmacy pair; mouse combo lifespan talk exists; human users discuss glucose monitoring because both can hit nutrient-sensing pathways. forum
- Clinic layering lore: Some longevity clinics start metformin ~90 days before adding weekly rapamycin to establish glycemic baseline — protocol culture, not a universal RCT. forum
- NAD axis: Frequently named with NMN or NR (± resveratrol, TMG/methyl donors) as a “metabolic aging” stack — attribution of benefits is confounded. forum
- Berberine alternative or co-agent: ~500 mg berberine 2–3×/day (≈1,000–1,500 mg/day) is the usual OTC comparator band; dual use raises GI and low-glucose watch. forum
- GLP-1 / dual agonist era: Compared, sequenced, or co-prescribed with semaglutide, tirzepatide, etc. under care — GLP-1s dominate weight; metformin remains glucose/cost baseline. forum
- Lifestyle as the real stack: Protein-forward diet, resistance training, zone-2, sleep, weight management — often outperform add-on pills for metabolic endpoints. forum
- Avoid naive “more AMPK” stacking: Metformin + berberine + hard fasting + other glucose drugs without labs is a repeated community caution theme. forum
- Bodybuilding adjacency: Sometimes paired with insulin/GH discussion for partitioning — high-risk enhanced context, not longevity default. forum
- Berberine + metformin + GLP: The 2025–26 crash screenshot. Forums tell people to pick one AMPK story or have a clinician watch glucose — not to triple it. forum
- Rapamycin + acarbose ± metformin: ITP-influenced “nutrient-sensing trio” talk; acarbose + rapa often highlighted for mouse median lifespan; metformin may or may not be third wheel. animal
- SGLT2 co-therapy (clinical diabetes): Common in modern T2D algorithms; not a bro longevity invention but appears in metabolic stacks. trial
- B12 co-support talk: Long-term users discuss B12 monitoring or supplementation because metformin is linked to lower B12. trial
Access talk
- Prescription generic IR / XR (Glucophage and copies) — cheap with a script, off-label for longevity. Not a research peptide. forum
- Telehealth / longevity-clinic off-label vs endocrinology T2D titration are different shelves. Do not treat Amazon berberine as the same bottle. forum
- No compounding-shortage story the way sema / tirz had. This is a decades-old generic. forum
- XR vs IR is the GI access hack, not a different molecule. trial
Labs people mention
- Lipids are a secondary metabolic screenshot, not metformin’s headline. forum
- Stacked with berberine or a GLP: CGM / “did it crash” is the 2025–26 watch. forum
- Glucose and HbA1c are the job labs. Longevity users still end up staring at the same numbers. trial
- eGFR gates whether people keep the drug. B12 is the long-term add-on conversation. trial
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Metallic taste: Dysgeusia is classic and can kill adherence. forum
- Low-glucose concerns: Metformin alone rarely causes hypoglycemia. The label flags insulin/sulfonylurea combinations and also warns about inadequate food, alcohol and other glucose-lowering medicines. Existing forum notes flag GLP-1 combinations, aggressive fasting and multi-agent AMPK stacks; these are not all equivalent proven interactions. Fatigue alone does not confirm low glucose or B12 deficiency. trialforum
- Complex I / mitochondrial debate: Mechanistic concern that Complex I inhibition interferes with training signals — mixed human data, not a universal ban, but central to longevity-lifter arguments. forum
- Influencer reverse course: High-profile longevity clinicians (e.g. Attia public discussion) have reduced or stopped personal metformin after exercise-adaptation data — cultural signal, not a trial endpoint. anecdote
- Not risk-free off-label: Long Rx history in diabetes ≠ automatic safety for healthy self-experimentation without labs and medical context. forum
- Label vs longevity clinic: Off-label healthy-aging scripts do not change the FDA indication. 2026 rooms still argue TAME; they do not have a published aging-indication win. forum
- GI (most common): Diarrhea, nausea, bloating, gas, abdominal pain, loss of appetite — worst at initiation and dose jumps; major reason for early quit. trial
- XR rescue: Switching intolerant IR users to XR often cuts diarrhea/nausea enough to continue. trial
- Vitamin B12: Long-term use associated with lower B12; screening/supplement talk is standard in clinic culture; risk rises with dose and duration. trial
- Lactic acidosis (rare but serious): Metformin-associated lactic acidosis when drug accumulates — renal failure, severe illness, hypoxia, hepatic failure, heavy alcohol — can be fatal. trial
- Contrast / procedure risk: Iodinated contrast + renal vulnerability is the textbook hold scenario (label vs ACR nuances exist). trial
- Training adaptations — MASTERS: RCT in older adults, metformin 1,700 mg/day during ~14 weeks progressive resistance training — less lean mass and thigh muscle gain vs placebo (often summarized ~half the hypertrophy response / ~0.8 vs ~1.5 kg lean mass class figures). trial
- Cardio / vascular adaptations: Later exercise studies (including 2025 Rutgers-led discussion of blunted vessel, fitness, and glucose-training benefits) keep the “metformin + exercise may not be simply additive” narrative alive. trial
- Alcohol: Excess alcohol + metformin is a repeated lactic-acidosis risk teaching point. trial
- Pregnancy / special populations: Separate clinical rules (gestational diabetes is a different supervised context) — not longevity-stack copy-paste. trial
- Phenformin lesson: Older biguanide withdrawn for lactic acidosis — why metformin’s renal rules exist. trial
- Kidneys gate use: eGFR-based start/stop rules; many systems stop at eGFR <30 and reassess/reduce in 30–45 range — know renal status before any research framing of dose. trial
Evidence mix
More trial/lab tags than forum tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.